Are Ketamine Clinics Legal in the U.S.?

The Permission No One Granted

No federal agency has ever authorized the ketamine clinic as a category of medical practice. There is no licensing pathway. There is no registration type. There is no application a physician submits to the DEA, to the FDA, or to any state medical board that bears the words “ketamine infusion clinic” in its caption. The ketamine clinic exists because nothing in the law prohibits a physician with an active DEA registration from prescribing and administering a Schedule III controlled substance for off-label indications in a clinical setting, and the law’s silence on the question of whether this particular configuration of prescription authority, real estate, and therapeutic intention constitutes a distinct form of medical practice has been interpreted, by more than fifteen hundred operators across the country, as consent.

It is not consent. It is the absence of prohibition, which is a different foundation on which to construct a business that generates revenue from the administration of a federally controlled substance to patients whose conditions the FDA has never approved that substance to treat.

And yet the clinics are, under current law, legal.

The Regulatory Silence That Serves as Architecture

The Controlled Substances Act, enacted in 1970 and amended with frequency in the decades since, does not contain a provision addressing the administration of ketamine for psychiatric indications. The FDA, which approved ketamine in 1970 under the trade name Ketalar for use as an anesthetic agent, has not approved it for treatment-resistant depression, for anxiety disorders, for post-traumatic stress, or for any of the conditions that constitute the primary clinical offering of the overwhelming majority of ketamine clinics in operation. The DEA, which placed ketamine into Schedule III through a final rule effective August 12, 1999, regulates its manufacture, distribution, dispensing, and record-keeping without distinguishing between the anesthesiologist who administers it in a surgical theater and the psychiatrist who administers it in a leased suite on the second floor of a medical office building for the treatment of a condition the scheduling rule never contemplated.

The physician who opens a ketamine clinic does so under general medical practice authority. The authority derives from state licensure, from the DEA registration that permits prescribing and dispensing of Schedule III substances, and from the physician’s own determination that the off-label use of ketamine for a given patient constitutes the exercise of legitimate clinical judgment within the usual course of professional practice. No separate credential is required. No separate inspection precedes the opening. The physician hangs a sign, orders ketamine from a distributor, and begins treating patients under the same regulatory framework that governs the prescription of testosterone or codeine preparations.

Whether the absence of a specialized regulatory framework represents a deliberate policy choice or an institutional failure to anticipate the pace at which a surgical anesthetic would be repurposed for psychiatric treatment is a question worth considering.

The States Have Begun to Speak

Utah was among the first to impose specific obligations on ketamine clinic operators. In 2022, the state legislature passed SB 197, codified at Section 58-1-510 of the Utah Code, requiring that any provider administering non-anesthetic ketamine infusions maintain sedation-trained staff on site during the procedure and comply with patient monitoring standards that the statute defines with a specificity the federal government has never approached. The law did not declare ketamine clinics illegal. It declared them regulated, which accomplished what the federal silence had not.

Missouri House Bill 1043 proposed mandatory physician supervision requirements and documented treatment plans for every ketamine administration for mental health purposes. Hawaii Senate Bill 967 proposed requiring Medicaid and private insurance coverage for intravenous ketamine therapy administered under licensed medical supervision. Colorado, proceeding from its broader posture toward psychedelic reform, has constructed a framework that accommodates ketamine-assisted therapies within a regulatory environment less restrictive than most.

We addressed the state-by-state variation in prescribing authority in a prior examination of whether physicians require a separate DEA registration for ketamine, and the analysis there extends to the clinic question with a complication the registration article did not reach: the corporate structure of the clinic itself.

The Doctrine That Determines Who May Own the Practice

The corporate practice of medicine doctrine, which prohibits lay entities from practicing medicine or employing physicians for the provision of medical services, operates in approximately thirty states with varying degrees of rigor. In California, New York, Texas, Illinois, and Washington, the doctrine requires that a medical practice be owned by a licensed physician or a professional corporation whose shareholders hold medical licenses. A venture capital firm, a technology company, or an entrepreneur without a medical license cannot own the entity that employs the physicians who administer ketamine. The doctrine exists to prevent commercial interests from influencing clinical judgment, and its application to ketamine clinics has produced a structural arrangement that pervades the industry: the management services organization.

The MSO provides administrative services to the physician-owned practice. It manages billing, marketing, scheduling, lease negotiations, and strategic planning. It does not practice medicine. It does not employ the physician for the purpose of rendering medical services. The physician retains clinical autonomy. The arrangement is lawful in most jurisdictions if structured with precision. If structured without precision, it constitutes the unlicensed corporate practice of medicine, and the consequences include disciplinary action by the state medical board, potential criminal liability for aiding and abetting the unauthorized practice of medicine, and the retroactive invalidation of the contractual arrangements upon which the clinic’s financial model depends.

The investor who finances the clinic and the physician who operates it must occupy separate legal compartments, and the wall between those compartments must be constructed from documents whose language the medical board will read with the disposition of an institution that regards commerce in the examination room as a contaminant.

In states that do not enforce the doctrine, or enforce it with the leniency that characterizes Oregon’s approach prior to its recent legislative proposals, the ownership question resolves with less friction. But even in permissive jurisdictions, the physician’s clinical independence must remain visible in the corporate governance documents, the employment agreements, and the operational protocols the entity maintains, because the absence of a state-level prohibition does not immunize the arrangement from federal scrutiny if the DEA concludes that the clinic’s prescribing patterns reflect commercial motivations rather than clinical ones.

The Compounding Relationship That Binds Prescriber to Pharmacy

Most ketamine prescribed for psychiatric indications is compounded. A 503A pharmacy formulates sublingual troches, nasal sprays, and oral solutions pursuant to individual patient prescriptions. A 503B outsourcing facility manufactures larger batches for distribution to healthcare providers for office administration. The physician who prescribes compounded ketamine does not assume the pharmacy’s compliance obligations, but the prescribing record and the compounding record together constitute the evidentiary chain the DEA will reconstruct if either entity attracts investigation.

The constructive transfer question has burdened this relationship for two decades. The DEA has maintained the position that a pharmacy may not transfer a patient-specific controlled substance prescription to the prescribing physician for safekeeping and subsequent administration, because such a transfer constitutes a second dispensing event the Controlled Substances Act did not authorize. A 2016 DEA letter indicated that the agency might exercise enforcement discretion for single-dose transfers, but the letter does not carry the force of law, and the Alliance for Pharmacy Compounding noted in its April 2024 best practices document that the agency’s limited enforcement actions in this area do not constitute a reliable basis for operational planning.

The clinic that receives compounded ketamine from a pharmacy and maintains it on the premises for patient administration must ensure that the chain of custody satisfies the DEA’s record-keeping requirements at every point of transfer. The quantity ordered must correspond to the quantity received. The quantity received must correspond to the quantity administered. The quantity administered must correspond to the patient records that document the clinical rationale for each dose. A discrepancy at any point in the chain produces the arithmetic the agency has applied, with increasing precision since 2023, to every controlled substance it monitors. The compounding pharmacy’s compliance failures become the clinic’s exposure. The relationship, once established, cannot be severed from the regulatory consequences it generates.

The Informed Consent That No Standard Governs

There is no consensus standard of care for the administration of ketamine for psychiatric indications. The field is too new. The clinical protocols vary between clinics, between physicians, between the professional organizations that have published competing recommendations, and the absence of consensus means that the informed consent document the patient signs before the first infusion occupies a position of unusual legal significance, because the document must articulate risks and benefits for a treatment whose parameters the medical profession has not agreed upon.

A 2023 review of informed consent documents across ketamine therapy clinics found that the documents varied in content, in comprehensiveness, and in readability, with all assessed documents scoring at a level the researchers characterized as poor for patient comprehension. The document that the patient could not understand becomes, in the malpractice proceeding that follows an adverse outcome, the document the clinic cannot rely upon to establish that the patient assumed the risk the document was intended to communicate.

The FDA’s warning on compounded ketamine products, issued in October 2023 and reiterated in subsequent communications, stated that the agency had not determined compounded ketamine to be safe and effective for psychiatric use and that the absence of monitoring for adverse events such as sedation and dissociation by an on-site healthcare provider placed patients at risk. The warning did not prohibit prescribing. It created the evidentiary foundation for a malpractice claim whose central allegation is that the provider knew, or should have known, that the federal agency responsible for drug safety had expressed reservations about the treatment the provider administered without monitoring the patient for the specific adverse events the agency identified.

The informed consent form bears the weight of that knowledge. Whether it bears it adequately is a question most clinics have not submitted to counsel for evaluation.

The Telehealth Model and Its Provisional Foundation

The DEA’s Fourth Temporary Extension of COVID-19 Telemedicine Flexibilities, published December 31, 2025, permits the prescribing of Schedule II through V controlled substances via telemedicine without a prior in-person evaluation through December 31, 2026. The extension preserves the legal basis upon which every telehealth ketamine provider operates, and it preserves the temporary character of that basis with a candor the agency has maintained since the first extension. The Ryan Haight Online Pharmacy Consumer Protection Act of 2008 prohibits precisely this form of prescribing in its default operation. The flexibilities suspend the prohibition. The suspension has been renewed four times. It has not been made permanent.

The telehealth ketamine provider who evaluates a patient by video, prescribes compounded ketamine lozenges, and has them shipped to the patient’s home through a mail-order pharmacy has constructed a clinical operation upon a regulatory permission that the agency characterizes, in its own language, as temporary, and whose permanent replacement, if one arrives, will impose registration, record-keeping, and security requirements that the proposed Special Registration for Telemedicine has outlined but not finalized. When the Mindbloom wrongful death lawsuit was filed in October 2025, alleging that the telehealth provider failed to screen a patient whose medical history should have disqualified him from unsupervised at-home ketamine use, the case articulated a liability theory that the regulatory gap between in-clinic administration and at-home self-administration had been producing in silence for years.

DEFENSE TEAM SPOTLIGHT

Todd Spodek

Lead Attorney & Founder

Featured on Netflix's "Inventing Anna," Todd Spodek brings decades of high-stakes criminal defense experience. His aggressive approach has secured dismissals and acquittals in cases others deemed unwinnable.

NY Bar Admitted Multi-State Licensed Federal Courts

Meet the Full Team

The clinic that administers ketamine in a treatment room monitors the patient for two hours. The telehealth service that mails ketamine to the patient’s residence monitors nothing but the billing cycle.

The Enforcement Record That Answers the Question

In January 2024, a federal grand jury in the Eastern District of Missouri returned a twenty-two-count indictment against Dr. Asim Ali and Dr. Mohd Malik in connection with the COPE Ketamine Clinic. The charges included conspiracy to distribute controlled substances, healthcare fraud, and maintaining drug-involved premises. In August 2024, the Central District of California charged five defendants in the Matthew Perry case, including two physicians whose sentences, thirty months and eight months respectively, were imposed under the same distribution statutes that govern opioid prosecutions. DEA Administrator Anne Milgram compared the ketamine market to the early stages of the opioid epidemic. That comparison was not an analogy. It was an announcement.

The clinics are legal. The operations within the clinics may not be. The distance between those two propositions contains the entire enforcement environment of this industry in the spring of 2026, and the practitioner who conflates the legality of the business form with the legality of the business conduct has misunderstood the nature of the permission under which the clinic operates. The DEA does not prosecute the existence of the clinic. It prosecutes what occurs inside.

The Permission That Requires Construction

A ketamine clinic that maintains a current DEA registration at each location where ketamine is administered, that employs or contracts with physicians whose state licenses authorize the prescribing of Schedule III controlled substances, that documents clinical rationale for each patient’s treatment with the specificity the agency’s investigators expect, that reconciles inventory with dispensing records at intervals no investigator could characterize as inadequate, that obtains informed consent through a document whose content has been reviewed by counsel familiar with the FDA’s communications regarding compounded ketamine, that structures its corporate governance to satisfy the corporate practice of medicine doctrine in its state of operation, and that maintains the chain of custody for every milligram of ketamine from the distributor’s invoice to the patient’s medical record, operates within the law.

A clinic that omits any element of that architecture does not become illegal. It becomes vulnerable. The distinction between legal and vulnerable is the distinction between a clinic that can withstand inspection and a clinic that cannot, and the DEA’s inspection authority does not require probable cause, does not require a warrant, and does not require the courtesy of prior notice.

The question the practitioner should have asked was never whether ketamine clinics are legal. The question is whether this particular clinic, with its particular documentation, its particular corporate structure, its particular relationship to its compounding pharmacy, and its particular informed consent protocols, can sustain the regulatory scrutiny that the enforcement environment of this period has rendered probable rather than theoretical. That assessment begins with a consultation, and the consultation is the instrument that distinguishes the clinic that operates within the permission from the clinic that merely assumes it does. The conversation this firm conducts addresses the architecture before the agency arrives to examine it.

Outside the walls of the infusion suite, in the rulemaking dockets and the enforcement bulletins and the legislative committees of thirty state capitols, the regulatory apparatus is assembling itself around an industry that grew in the silence between what the law permitted and what the law intended, and the distance between those two conditions has never been permanent.